

RE: FOI 24/179 Ritlecitinib (Litfulo) for severe alopecia areata public assessment report

FOILicensing <FOILicensing@mhra.gov.uk>

Thu 07/03/2024 15:45

To [REDACTED]

Cc:MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

Dear [REDACTED]

Regarding your email of 22 February 2024, where you requested the Public Assessment Report (PAR) for “Ritlecitinib (Litfulo) for severe alopecia areata.”

A marketing authorisation was granted for Litfulo 50 mg hard capsules (PLGB 00057/1715) on 02 November 2023 for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

A PAR is currently being prepared for this marketing authorisation and should be available in the next 2 months.

As the requested information will be published, in accordance with our publication schedule, we are exempting release under Section 22 of the Freedom of Information (FOI) Act.

Section 22

(1) Information is exempt information if—

(a) the information is held by the public authority with a view to its publication, by the authority or any other person, at some future date (whether determined or not),

(b) the information was already held with a view to such publication at the time when the request for information was made, and

(c) it is reasonable in all the circumstances that the information should be withheld from disclosure until the date referred to in paragraph (a).

Each of the three criteria must be met for section 22(1) to be engaged. The assessment reports are held by the MHRA with the settled expectation that this PAR will be published at a future date; in this case, this expectation is based on the section 64 of the Human Medicines Regulations 2012, which sets out the duties of the MHRA for the publication of PARs:

Duties of licensing authority in connection with determination

(6) The licensing authority must—

(b) make the assessment report publicly available (with the omission of information of a commercially confidential nature) as soon as is reasonably practicable after it has been prepared or revised; and

(c) include in the assessment report a summary, written in a manner that is understandable to the public, that contains, in particular, a section relating to the conditions of use of the medicinal product.

As stated in section 22(1)(a), it is not necessary for the date of publication to be determined for section 22(1) to apply.

We take a consistent approach to support the scheduled publication of PARs for wider public benefit. We believe it is reasonable in all the circumstances, fair, and in line with accepted practices, to withhold the information requested ahead of the wider schedule of publication. In this case, there is a settled intent to publish the PAR at a future date, and it is reasonable to maintain the schedule for this planned publication.

Public interest

We have considered the public interest within the process of engaging Section 22. A factor in favour is the general principle in transparency, to provide for earlier release of this particular information. We also understand there is a public interest in making the information available for public scrutiny. However, responding to individual requests on an ad hoc basis while the information requested forms part of the scheduled approach to wider publication, creates an additional burden for staff and disrupts the existing approach to the process. This factor strongly favours maintaining the exemption.

We therefore consider that section 22(1) applies to the requested information at this time.

We trust that you will understand the basis for why this approach has been taken. However, if you disagree with how we have interpreted the Freedom of Information Act 2000 in

answering your request, you can ask us to review our actions and decisions by writing to: info@mhra.gov.uk, and requesting an internal review.

Please note that your internal review request must be in a recordable format (email, letter, audio tape etc.), and that you have 40 working days upon receipt of this letter to ask for a review. We aim to provide a full response to your review request within 20 working days of its receipt. Please quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted online via an electronic form: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/>

Or in writing to:

Information Commissioner's Office,
Wycliffe House,
Water Lane,
Wilmslow,
Cheshire,
SK9 5AF

Yours sincerely,
HQA FOI Team

From: [REDACTED]

Sent: Thursday, February 22, 2024 11:58 AM

To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

Subject: FOI 24/179 Ritlecitinib (Litfulo) for severe alopecia areata public assessment report

Dear MHRA

I should be grateful if you would send me a copy of the Public Assessment Report for Ritlecitinib (Litfulo) for severe alopecia areata.

Many thanks.

Best wishes

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] knowledge provider with a vision for a healthier world. We share knowledge and expertise to improve healthcare outcomes. See how we are making a difference in our latest impact report:

[REDACTED] his email and any attachments are confidential. If you have received this email in error, please delete it and kindly notify us. If the email contains personal views then [REDACTED] accepts no responsibility for these statements. The recipient should check this email and attachments for viruses because the [REDACTED] accepts no liability for any damage caused by viruses. Emails sent or received by [REDACTED] may be monitored for size, traffic, distribution and content. [REDACTED] Publishing Group Limited trading as [REDACTED] A private limited company, registered in England and Wales under registration number 03102371. Registered office: [REDACTED]

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient,